# PIVOT-09: HCP commentary report

> 27 verified statements (2 from clinicians verified by NPI or staff page) from 8 commentary sources · 5 findings · updated Oct 30, 2026

## Report

- Trial: A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined With Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients With Previously Untreated Advanced Renal Cell Carcinoma
- NCT ID: NCT03729245
- Registry: https://clinicaltrials.gov/study/NCT03729245
- Sponsor: Nektar Therapeutics
- Phase: Phase 3
- Status: Terminated
- Drugs tested: bempegaldesleukin plus nivolumab
- Indication: previously untreated advanced clear cell renal cell carcinoma
- Version: v1.0.0, edition 1
- Accepted: 2026-10-30
- Last checked: 2026-10-30
- Release hash: cb24ad937aa058a864aab8fb11f24f401e3769978aa639f083106e64b8f2e55d

## Counts

- HCP commentary sources screened: 18
- Sources cited by verified statements: 11
- Verified statements: 27
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 2
- Findings: 5
- Named people in screened sources (unnamed speakers and accounts not counted): 6
- Voices cited: 6
- Cited voices identity-verified: 5
- Organisational or shared accounts (not counted as people): 1

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

PIVOT-09 asks whether bempegaldesleukin plus nivolumab improves response and survival over single-agent sunitinib or cabozantinib as initial therapy for advanced renal cell carcinoma. Commentary comes from X posts; clinical roles are not confirmed in the sources reviewed for this edition. The discussion turns on one speaker’s regimen-specific efficacy caution alongside reports of fewer high-grade adverse events, whether a possible PD-L1 subgroup benefit can guide selection, and how recognition of the trial’s contribution differs from efficacy endorsement.

## Open Medical Affairs question

How should Medical Affairs explain comparator relevance and regimen-specific benefit–risk without turning null comparisons or a tentative subgroup signal into equivalence or a selection rule?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Regimen-specific efficacy caution accompanies reports of fewer high-grade adverse events.
- F2. The usefulness of a single-agent TKI control was questioned
- F3. The possible PD-L1 subgroup benefit remains a selection hypothesis
- F4. Broader advanced-RCC commentary emphasizes patient priorities and cross-trial caution
- F5. Recognition of the trial’s contribution is distinct from efficacy endorsement

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 9 | 4 | 4 | 2 | none recorded | 3 |
| F2 | 2 | 2 | 2 | 1 | none recorded | 2 |
| F3 | 2 | 2 | 2 | 2 | none recorded | 2 |
| F4 | 4 | 3 | 1 | 1 | none recorded | 2 |
| F5 | 3 | 2 | 2 | 2 | none recorded | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 2 | 0 | 1 | 3 | 3 | 9 | 3 | 3 posts and articles, 1 publication | yes |
| F2 | 1 | 1 | 0 | 0 | 0 | 2 | 0 | 2 posts and articles | yes |
| F3 | 2 | 0 | 0 | 0 | 0 | 2 | 1 | 2 posts and articles | yes |
| F4 | 3 | 0 | 0 | 0 | 1 | 4 | 0 | 1 post or article | yes |
| F5 | 1 | 0 | 1 | 0 | 1 | 3 | 0 | 2 posts and articles | no |

### Trial dimensions

- Primary endpoint: Objective Response Rate (ORR) Per mRECIST 1.1 by BICR in IMDC All-risk Patients and Intermediate- or Poor (I/P)-Risk Patients With Previously Untreated Advanced RCC: F1 (2 shared claims)
- Primary endpoint: Overall Survival (OS) in IMDC All-Risk and Intermediate- or Poor-risk Patients With Previously Untreated Advanced RCC: F1 (4 shared claims), F3 (1 shared claims), F5 (2 shared claims)
- Secondary endpoint: Progression Free Survival (PFS) Per mRECIST 1.1 by BICR in IMDC All-risk Patients and Intermediate- or Poor (I/P)-Risk Patients With Previously Untreated Advanced RCC: F1 (2 shared claims), F5 (2 shared claims)
- Population and setting: F4 (2 shared claims)
- The comparison: F1 (3 shared claims), F2 (2 shared claims)
- Safety and tolerability: F1 (1 shared claims)
- Design and conduct: no finding draws on it directly

## Sample findings

Paraphrased; the full report links each statement to its source.

### F1. Regimen-specific efficacy caution accompanies reports of fewer high-grade adverse events.

How are response, survival and adverse events compared in an X thread relaying the trial presentation?

Source: X thread, 2022-09-12.

### F3. The possible PD-L1 subgroup benefit remains a selection hypothesis

What patient-selection questions do X posts raise about biomarkers in this treatment setting?

Source: X thread, 2022-09-12.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 5 | Titles free |
| Detailed analysis | 6 sections | Paid |
| Verified statements with short source quotes and links | 27 | Paid |
| Trial aspects mapped | 10 | Free |
| Sources with links | 11 | Counts free |
| Speaker attribution for cited voices | 6 | Paid |

## Trial aspects

9 discussed · 1 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Objective Response Rate (ORR) Per mRECIST 1.1 by BICR in IMDC All-risk Patients and Intermediate- or Poor (I/P)-Risk Patients With Previously Untreated Advanced RCC | discussed | 2 | 2 |
| Primary endpoint: Overall Survival (OS) in IMDC All-Risk and Intermediate- or Poor-risk Patients With Previously Untreated Advanced RCC | discussed | 4 | 3 |
| Secondary endpoint: Progression Free Survival (PFS) Per mRECIST 1.1 by BICR in IMDC All-risk Patients and Intermediate- or Poor (I/P)-Risk Patients With Previously Untreated Advanced RCC | discussed | 2 | 1 |
| Population and setting | discussed | 2 | 1 |
| The comparison | discussed | 5 | 4 |
| Safety and tolerability | discussed | 1 | 1 |
| Design and conduct | no commentary found | 0 | 0 |
| Tentative biomarker benefit and the need for better selection | discussed | 1 | 1 |
| Advanced-RCC treatment-selection context and cross-trial caution | discussed | 4 | 1 |
| Perceived scientific and collaborative value | discussed | 2 | 2 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 18 | 8 |
| Registry (primary source, cited for context) | not screened | 2 |
| Publications (primary source, cited for context) | not screened | 1 |

- Screened window: 2019-02-12 to 2024-06-10
- Cited window: 2019-02-12 to 2024-06-10
- Retrieved: 2026-10-30

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined With Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients With Previously Untreated Advanced Renal Cell Carcinoma
- Registry: NCT03729245 (https://clinicaltrials.gov/study/NCT03729245)
- Study IDs: 17-214-09 · CA045002 (Bristol-Myers Squibb Protocol ID)
- Sponsor: Nektar Therapeutics
- Collaborators: Bristol-Myers Squibb
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Terminated
- Enrollment: 623 (actual)
- Start: 2018-12-18 (actual)
- Primary completion: 2022-01-07 (actual)
- Primary endpoint: Objective Response Rate (ORR) Per mRECIST 1.1 by BICR in IMDC All-risk Patients and Intermediate- or Poor (I/P)-Risk Patients With Previously Untreated Advanced RCC (Approximately 32 months)
- Primary endpoint: Overall Survival (OS) in IMDC All-Risk and Intermediate- or Poor-risk Patients With Previously Untreated Advanced RCC (Approximately 32 months)
- Intervention: bempegaldesleukin (biological)
- Intervention: sunitinib (drug)
- Intervention: nivolumab (biological)
- Intervention: cabozantinib (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 13 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits apply, so some matching discussion may be missing.
- The sources reviewed for this edition are a selective set of public discussions, not a representative assessment of HCP opinion.
- Discussion omitting the trial name or using other shorthand may be absent. Some potentially relevant discussions were not read, and some passages were not fully assessed, so additional viewpoints may be missing.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- The presentation and publication summaries relayed by a speaker are not independent analyses by the speaker. Circulation through reposts does not establish additional authors’ endorsement.
- The posts often omit numerical estimates, risk-population details and statistical qualifications; the tentative subgroup statement is especially limited.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-30: current edition, corrected 2026-10-30
  - Correction 2026-10-30: Corrected to match the delivered report: the sample findings; the report description.

Last checked for new commentary 2026-10-30. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (27 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (5 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/pivot-09-nct03729245
- Agents: POST https://www.erudio.com/api/orders with {"report": "pivot-09-nct03729245", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=pivot-09-03729245

## Cite

Erudio Health. PIVOT-09 (NCT03729245): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 30, 2026. https://www.erudio.com/reports/pivot-09-nct03729245

## Machine access

- JSON: https://www.erudio.com/reports/pivot-09-nct03729245.json
- Markdown: https://www.erudio.com/reports/pivot-09-nct03729245.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "pivot-09-03729245"}`